CoChat

A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

Ikeda, S., Takano, Y., Cynshi, O., Tanaka, R., Christ, A. D., Boerlin, V., Beyer, U., Beck, A., Ciorciaro, C., Meyer, M., Kadowaki, T. · 2015 · Diabetes, Obesity and Metabolism
Cited by 73

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aim: To assess the efficacy, safety and tolerability of different doses of tofogliflozin, a novel, highly selective sodium‐glucose cotransporter 2 ( SGLT2 ) inhibitor, in patients with type 2 diabetes mellitus ( T2DM ). Methods: In a 12‐week, multicentre, multinational, randomized, double‐blind, parallel‐group, placebo‐controlled, dose‐finding study, patients with inadequate glycaemic control from diet and exercise alone, or from diet and exercise plus a stable dose of metformin, were randomized to one of five doses of tofogliflozin (2.5, 5, 10, 20, or 40 mg) or placebo. The primary efficacy endpoint was absolute change at week 12 from baseline in glycated haemoglobin ( HbA1c ), minus the change in the placebo group. Results: Statistically significant dose‐dependent reductions in HbA1c were shown in all treated groups except the 2.5‐mg dose group, with a maximum reduction of 0.56% (placebo‐subtracted) at the 40‐mg dose, along with increased urinary glucose excretion. Metformin treatment had no substantial influence on tofogliflozin efficacy. Dose‐dependent reductions in fasting plasma glucose and body weight were observed, and glucose intolerance was improved, with a trend towards blood pressure reduction. Slight increases were observed for mean ketone bodies with no abnormal change in ketone body ratio. No deaths or treatment‐related serious adverse events were reported. The incidence of adverse events was similar in the placebo (37.9%) to that in the tofogliflozin group (35.9–46.3%). Withdrawal because of adverse events was rare (≤2 patients per treatment group), with similar rates of withdrawal in the placebo and tofogliflozin groups. Conclusions: A once‐daily dose of tofogliflozin for 12 weeks was an effective, safe and well‐tolerated treatment for T2DM .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12538

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 73

Metadata

Authors
Ikeda, S., Takano, Y., Cynshi, O., Tanaka, R., Christ, A. D., Boerlin, V., Beyer, U., Beck, A., Ciorciaro, C., Meyer, M., & Kadowaki, T.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-08-20
Volume
17
Issue
10
Pages
984-993
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1869287998
Cited by
73
References
5
FWCI
6.33
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.